Skip to content

Kura Oncology (KURA) stock

Common stock · Nasdaq

Know the moment the smart money buys or sells Kura Oncology.

See who owns Kura Oncology, what its own executives are doing with their shares and what social media is saying, with an alert the moment any of it changes.

  • Every stock, fund, option and crypto you own, in one place.
  • News, fundamentals and technicals, explained by AI in plain English.
  • Congress, top fund managers, insiders, analysts and social media signals, with an alert the moment they move.

No credit card30 days of Pro free

Instaport’s take on Kura Oncology

Fair value
Overvalued

Our model’s fair value is , about below today’s price.

Quant score
/ 10
  • Momentum
  • Revisions
  • Profitability
  • Growth
  • Valuation
AI summary

Kura Oncology is down 35% over the past year, behind the S&P 500’s 12% gain.

See the full fair value, quant grades and AI summary, for Kura Oncology and every stock you own.
Sign up free

No credit card30 days of Pro free

Never be the last to know

When a top fund, Congress or Kura Oncology’s own executives buy or sell, you hear about it the day it goes public, not weeks later in the news.

Hours and days of research in minutes

Congress, top fund managers, insiders, analysts and social media, on every stock you own, in one glance. No more checking five websites.

Invest with confidence

AI explains what each move means for your portfolio in plain English, so you know what you own and why.

Kura Oncology at a glance

Price$7.49Nov 17 close
Day change+5.64%
52-week range$6.75 – $13.90
Market cap$688.17M
P/E-2.3
Next earnings—
Next-quarter EPS estimate—
Short interest13.76%of shares outstanding
Social chatter—
Past year: Kura Oncology −35% vs S&P 500 +12%Kura OncologyS&P 500

Who owns Kura Oncology

Top fund managers

Fund · manager% of their portfolioValue
Suvretta CapitalAaron Cowen1.97%$84.61M
Renaissance TechnologiesPeter Brown0.03%$21.48M
AQR Capital ManagementCliff Asness0.01%$39.51M

Kura Oncology’s executives: 12 sales and 4 open-market buys in their last 18 reported trades.

9 top funds and 0 members of Congress own Kura Oncology. See them all free →

Kura Oncology (KURA): funds that hold it

#Fund% of fund
1BBPVirtus Biotech ETF1.37%
2CANCTema Oncology ETF1.03%
3IDNAiShares Genomics Immunology and Healthcare ETF0.88%
4SBIOALPS Medical Breakthroughs ETF0.58%
5XBIState Street SPDR S&P Biotech ETF0.32%
6HAPSHarbor Human Capital Factor US Small Cap ETF0.31%
7LABUDirexion Daily S&P Biotech Bull 3X ETF0.19%
8RFLRInnovator U.S. Small Cap Managed Floor ETF0.13%
9FSEGFidelity Enhanced Small Cap Growth ETF0.11%
10SMMViShares MSCI USA Small-Cap Min Vol Factor ETF0.10%

Questions about Kura Oncology stock

Is Kura Oncology stock overvalued?

Instaport’s fair value model currently rates Kura Oncology as overvalued compared with the cash it is expected to generate. Create a free account to see the fair value estimate and the range behind it.

Which top fund managers own Kura Oncology stock?

Aaron Cowen’s Suvretta Capital holds KURA, about 2% of its portfolio (roughly $84.6M) as of its latest filing. Peter Brown’s Renaissance Technologies and Cliff Asness’s AQR Capital Management are also large holders.

Are Kura Oncology insiders buying or selling?

Mostly selling. Kura Oncology insiders made 12 sales and 4 open-market buys in their last 18 reported transactions.

Power your portfolio with AI.

Know what’s moving your investments in minutes, so you can invest better.

Sign up free

No credit card30 days of Pro free

Information and analytics, not investment advice.